Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

2014 ASCO Annual Meeting

Published: 1 Jun 2014

Views: 2919

Rating:

Save

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

At a press conference at ASCO 2014, Prof Sweeney presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.

Read the article for more.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Management of prostate cancer in Africa: Looking to the future

Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA

Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Digital rectal examination is not useful as a solitary screening tool for...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

More from ecancer